TempraMed Technologies Ltd.

Validation is expected to accelerate TempraMed’s path to payor reimbursement for product portfolio Highlights -          ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility-          Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment-          Supports TempraMed’s planned...

Vancouver, BC – January 12, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each,...

Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activities Vancouver, BC - January 7, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial...

Vancouver, BC – January 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead...

Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected “VIVI Cap Smart” device Vancouver, BC – December 31, 2025 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed,...

Integrated smart technology builds on TempraMed’s proven VIVI platform, providing robust Temperature control with  medication management for individuals using life-saving medication Highlights:  Expands TempraMed’s product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost  every insulin and GLP-1 pens to...

New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for products Highlights:  -          Manufacturing site in Florida expands TempraMed’s U.S. production footprint-          Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers-          Shortens delivery...

Highlights -          Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture-          Expands the Company’s ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics-          Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia’s premium...

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership. Vancouver, BC – December 10, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr....

Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI...

Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company...

-          Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction -          Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance -          One of many distribution...